The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnilever Regulatory News (ULVR)

Share Price Information for Unilever (ULVR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,188.00
Bid: 4,185.00
Ask: 4,187.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.048%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 4,188.00
ULVR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Non-Executive Director appointment

13 Oct 2021 15:15

RNS Number : 9890O
Unilever PLC
13 October 2021
 

Appointment of Non-Executive Director

 

 

London, 13 October 2021 - Unilever PLC today announces that Ruby Lu has been appointed as a Non-Executive Director of the company, with effect from 1 November 2021. Ruby will join both the Compensation Committee and the Nominating and Corporate Governance Committee upon appointment.

 

Nils Andersen, Chairman of Unilever, said: "I am very pleased that Ruby has agreed to join the Board. She has had a successful executive career, and will further strengthen the Board with her extensive financial and global market experience".

 

Ruby is a venture capitalist investing in technology start-ups in the U.S. and China. Ruby founded Atypical Ventures, an early-stage technology venture investment firm, in 2019. In 2006, she co-founded DCM China, a venture capital firm. During her more than 12-year tenure at DCM, she invested in, and served as a board member for, many leading technology companies. Prior to joining DCM in 2003, Ruby was a vice president in the investment banking group of technology, media and telecommunications at Goldman Sachs & Co.

 

Ruby is currently a Non-Executive Director at Uxin Limited and Yum China. Within the last five years, Ruby has been a Non-Executive Director at two other companies which were publicly quoted during such time: Blue City Holdings Limited and Ikang Healthcare Group. There are no additional matters that require disclosure under 9.6.13R of the UK Listing Rules.

 

 

 

Media:  Media Relations team

 +44 78 2527 3767

lucila.zambrano@unilever.com

Investors: Investor Relations team

 +44 20 7822 6830

investor.relations@unilever.com

 

 

-ends-

 

 

 

This announcement may contain forward-looking statements, including 'forward-looking statements' within the meaning of the United States Private Securities Litigation Reform Act of 1995. Words such as 'will', 'aim', 'expects', 'anticipates', 'intends', 'looks', 'believes', 'vision', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Unilever Group (the 'Group'). They are not historical facts, nor are they guarantees of future performance.

 

Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: Unilever's global brands not meeting consumer preferences; Unilever's ability to innovate and remain competitive; Unilever's investment choices in its portfolio management; the effect of climate change on Unilever's business; Unilever's ability to find sustainable solutions to its plastic packaging; significant changes or deterioration in customer relationships; the recruitment and retention of talented employees; disruptions in our supply chain and distribution; increases or volatility in the cost of raw materials and commodities; the production of safe and high quality products; secure and reliable IT infrastructure; execution of acquisitions, divestitures and business transformation projects; economic, social and political risks and natural disasters; financial risks; failure to meet high and ethical standards; and managing regulatory, tax and legal matters. A number of these risks have increased as a result of the current Covid-19 pandemic. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Further details of potential risks and uncertainties affecting the Group are described in the Group's filings with the London Stock Exchange, Euronext Amsterdam and the US Securities and Exchange Commission, including in the Annual Report on Form 20-F 2020 and the Unilever Annual Report and Accounts 2020 available on our corporate website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGZMMGDFKGMZM
Date   Source Headline
1st May 20244:10 pmRNSResult of AGM
1st May 20243:17 pmRNSCommittee Composition
1st May 20249:06 amRNSTotal Voting Rights
25th Apr 20247:00 amRNSQ1 2024 Trading Statement
2nd Apr 20243:58 pmRNSTotal Voting Rights
28th Mar 20245:04 pmRNSDirector/PDMR Shareholding
27th Mar 202412:32 pmRNSDirector/PDMR Shareholding
26th Mar 20246:13 pmRNSDirector/PDMR Shareholding
26th Mar 202411:58 amRNSDirector/PDMR Shareholding
25th Mar 20243:10 pmRNSDirector/PDMR Shareholding
19th Mar 20247:00 amRNSUnilever to accelerate Growth Action Plan
18th Mar 20243:00 pmRNSNotice of AGM
14th Mar 20242:14 pmRNSAnnual Financial Report
13th Mar 20247:00 amRNSBlock Listing of Shares
11th Mar 20245:55 pmRNSDirector/PDMR Shareholding
1st Mar 20242:36 pmRNSTotal Voting Rights
19th Feb 20243:14 pmRNSDirector/PDMR Shareholding
8th Feb 20247:00 amRNSFinal Results
1st Feb 20245:04 pmRNSTotal Voting Rights
31st Jan 20243:00 pmRNSDirectorate Change
16th Jan 20245:10 pmRNSBlock listing Interim Review
2nd Jan 20242:54 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20235:48 pmRNSDirector/PDMR Shareholding
12th Dec 20235:51 pmRNSDirector/PDMR Shareholding
11th Dec 20235:48 pmRNSDirector/PDMR Shareholding
11th Dec 20235:43 pmRNSDirector/PDMR Shareholding
4th Dec 20235:28 pmRNSTotal Voting Rights
23rd Nov 20233:51 pmRNSDirector/PDMR Shareholding
22nd Nov 20235:44 pmRNSDirector/PDMR Shareholding
10th Nov 20235:33 pmRNSDirector/PDMR Shareholding
8th Nov 20236:05 pmRNSDirector/PDMR Shareholding
1st Nov 20233:36 pmRNSTotal Voting Rights
30th Oct 20234:33 pmRNSStatement re Director Remuneration Report AGM Vote
26th Oct 20237:01 amRNSUnilever Announces New CFO
26th Oct 20237:00 amRNS3rd Quarter Results
18th Oct 20232:00 pmRNSCompletion of the 4th Tranche Share Buyback
17th Oct 20235:57 pmRNSTransaction in Own Shares
16th Oct 20236:01 pmRNSTransaction in Own Shares
13th Oct 20235:58 pmRNSTransaction in Own Shares
12th Oct 20235:50 pmRNSTransaction in Own Shares
12th Oct 20239:04 amRNSChanges to Membership of Board Committees
11th Oct 20236:06 pmRNSTransaction in Own Shares
11th Oct 20234:37 pmRNSDirector/PDMR Shareholding
10th Oct 20235:42 pmRNSTransaction in Own Shares
9th Oct 20236:05 pmRNSTransaction in Own Shares
6th Oct 20235:55 pmRNSTransaction in Own Shares
5th Oct 20235:46 pmRNSTransaction in Own Shares
4th Oct 20235:54 pmRNSTransaction in Own Shares
3rd Oct 20235:40 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.